Nav: Home

No relief in sight for those suffering from sciatica

March 22, 2017

A drug increasingly being prescribed for treating sciatica has been revealed to be no better than placebo, in new research from The George Institute for Global Health.

The study in the New England Journal of Medicine also found people taking the drug pregabalin reported nearly twice as many adverse effects than those receiving the placebo.

Associate Professor Christine Lin from The George Institute for Global Health, Sydney, said: "We have seen a huge rise in the amount of prescriptions being written each year for patients suffering from sciatica. It's an incredibly painful and disabling condition so it's no wonder people are desperate for relief and medicines such as pregabalin have been widely prescribed.

"But, until now there has been no high quality evidence to help patients and doctors know whether pregabalin works for treating sciatica. Our results have shown pregabalin treatment did not relieve pain, but did cause side effects such as dizziness."

Sciatica is pain, tingling or numbness along the distribution of the sciatic nerve, most commonly caused by irritation of the nerve roots. Pain is mostly felt in the lower limbs but can be accompanied by back pain.

Since its first approval in 2004 pregabalin (sold as Lyrica) has become the most widely prescribed medicine for neuropathic pain globally, with worldwide sales of between $3-5 billion annually.

At any one time around 12% of the world's population has low back pain. It is estimated that around five to 10% of people with low back pain will have sciatica.

Researchers from the Musculoskeletal Division at The George Institute undertook the study after being increasingly concerned about the rise in the use of pregabalin, limited data on its effectiveness and fears over the drug's safety. One of the possible serious side effects is suicidal thoughts or actions. Pregabalin is used for a number of painful conditions that include neuropathic pain.

The research team at The George Institute followed 209 patients with sciatica in Sydney, Australia, who received pregabalin or a placebo capsule. After eight weeks there was no significant difference in pain intensity between the group taking pregabalin and those receiving the placebo and over one year no significant difference in the amount of days lost from work.

Despite the findings almost two thirds of patients on the study reported being very satisfied or satisfied with their drug regimen.

Associate Professor Christine Lin, of The George institute, said: "Over the course of eight weeks the levels of pain that patients experienced did decrease but the drop in pain was the same for both those taking the drug and those on placebo. It seems people associate a drop in pain being due to taking a capsule, rather than something which would happen naturally over time. GPs who are prescribing pregabalin should take note of these findings, and talk with their patients about other ways of managing and preventing pain.

"Unfortunately there are no drugs proven to work for people with sciatica and even epidural injections only provide a small benefit in the short term. What we do know is that most people with sciatica do eventually recover with time. It's also important to avoid bed rest and to stay as active as possible."

The team found no increase in the risk of self-harm, however the trial was not set up to detect risk of suicide so GPs are advised to exercise caution when prescribing.
-end-
This study was led by researchers from The George Institute in collaboration with researchers from The University of Sydney, University of New South Wales and Macquarie University.

For more information about managing sciatica and low back pain go to: http://annals.org/aim/article/736950/diagnosis-treatment-low-back-pain-recommendations-from-american-college-physicians

George Institute for Global Health

Related Pain Articles:

Spinal manipulation treatment for low back pain associated with modest improvement in pain, function
Among patients with acute low back pain, spinal manipulation therapy was associated with modest improvements in pain and function at up to six weeks, with temporary minor musculoskeletal harms, according to a study published by JAMA.
Pain in the neck
Researchers led by University of Utah bioengineering assistant professor Robby Bowles have discovered a way to curb chronic pain by modulating genes that reduce tissue- and cell-damaging inflammation.
Can staying active help to prevent chronic pain? Physical activity affects pain modulation in older adults
Older adults with higher levels of physical activity have pain modulation patterns that might help lower their risk of developing chronic pain, reports a study in PAINĀ®, the official publication of the International Association for the Study of Pain (IASP).
Is back pain killing us?
Older people who suffer from back pain have a 13 per cent increased risk of dying from any cause, University of Sydney research has found.
Improving pain care through implementation of the Stepped Care Model for Pain Management
A new study published in the Journal of Pain Research provides evidence that implementation of a Stepped Care Model for Pain Management has the potential to more adequately treat chronic pain.
Surgery for back pain reduces problems with sex life-related pain
For patients with degenerative spinal disease, surgery is more effective in reducing pain that interferes with sexual activity, compared to nonsurgical treatment, reports a study in the Nov.
'Pain paradox' discovery provides route to new pain control drugs
A natural substance known to activate pain in the central nervous system has been found to have the opposite effect in other parts of the body, potentially paving the way to new methods of pain control.
Treating pain without feeding addiction: Study shows promise of non-drug pain management
A new study shows the potential for patients who have both addiction issues and chronic pain to get relief from an approach that combines behavioral therapy and social support to help them manage their pain without painkillers that carry an addiction risk.
Neuropathic pain unmasks subliminal excitation in pain processing circuits
Research by Steven Prescott, at Toronto's Hospital for Sick Children, sheds new light on the mechanism underlying the establishment of neuropathic pain.
The anatomy of pain
Emotions consist of general components that are also elicited by similar impressions and specific components.

Related Pain Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.